MedHub-AI is a technology company.
MedHub-AI has raised $1.0M across 1 funding round.
MedHub-AI has raised $1.0M in total across 1 funding round.
MedHub-AI is an Israeli health tech company founded in 2018 that develops AI-powered software for cardiologists, focusing on non-invasive analysis of coronary angiograms to improve clinical decision-making and patient outcomes.[1][2][4] Its flagship product, AutocathFFR, is a fully automated Software as a Medical Device (SaMD) that computes fractional flow reserve (FFR) values from standard X-ray images in 37 seconds, eliminating the need for invasive guidewires or drugs, thereby reducing post-procedure risks, unnecessary interventions, and costs while enhancing care accessibility.[1][4] The company serves interventional cardiologists in catheterization labs, addressing workflow inefficiencies and diagnostic inaccuracies in coronary artery disease assessment, with strong growth evidenced by PMDA approval in Japan in June 2025 and a distribution deal with Terumo Corporation, plus impending U.S. FDA clearance.[4]
Upcoming products like AutocathML for diffuse coronary disease and AutocathMVD for microvascular dysfunction signal expanding momentum in AI-driven cardiology tools.[1]
MedHub-AI was founded in early 2018 by Or Bruch El, its CEO, in Tel Aviv, Israel, with the mission to leverage AI and machine learning for better cardiology care.[1][2] Bruch El, with prior experience running ventures like a real-time VR training platform for physicians (VRMS) and a video content distribution service (Scallopress), envisioned simplifying cardiologists' workflows amid rising demands for precise, efficient diagnostics.[1]
The idea emerged from recognizing AI's potential to analyze angiogram videos in real-time, providing actionable insights without invasive procedures. Early traction built through deep-learning algorithms for stenosis detection and FFR computation, culminating in a pivotal multicenter AI-FFR study across U.S. and Israeli hospitals, which validated 93.7% diagnostic accuracy.[4] Key advisors like Prof. Gregg Stone and Japan healthcare veteran Junichi Osawa bolstered credibility, driving regulatory milestones.[1][4]
MedHub-AI rides the wave of AI in precision medicine, particularly non-invasive cardiology diagnostics, amid surging demand for tools that cut procedural risks and costs in an aging population with rising cardiovascular disease.[1][4] Timing aligns with regulatory shifts favoring SaMD—evidenced by swift PMDA nod and FDA progress—fueled by post-pandemic emphasis on efficient, accessible care and AI's validated accuracy in imaging.[4]
Market tailwinds include interventional cardiology's growth (projected multi-billion scale) and AI adoption in medtech, where deep learning excels at video analysis for real-time guidance.[2] By influencing cath lab standards, MedHub-AI accelerates AI's shift from research to routine practice, potentially lowering global healthcare burdens while enabling emerging markets like Japan to leapfrog invasive tech.[1][4]
MedHub-AI is poised for U.S. market entry post-FDA approval, likely spurring partnerships and adoption in high-volume cath labs, with AutocathML and AutocathMVD expanding its portfolio to capture more of the coronary physiology segment.[1][4] Trends like multimodal AI integration and real-world evidence from Terumo's distribution will shape its path, amplifying influence as AI transforms cardiology from reactive to predictive care—echoing its founding vision of efficient, affordable outcomes for all patients.[1]
MedHub-AI has raised $1.0M in total across 1 funding round.
MedHub-AI's investors include AiSprouts VC, Earth and beyond ventures, GSF Accelerator, Hearst Ventures, NXTP Labs, Surround Ventures, Oded Hermoni.
MedHub-AI has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $1.0M Series A | AiSprouts VC, Earth and beyond ventures, GSF Accelerator, Hearst Ventures, NXTP Labs, Surround Ventures, Oded Hermoni |